The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.

Omitting completion axillary lymph node dissection does not increase risk for death for patients with clinically node-negative breast cancer, but it does significantly improve arm distress.Data from ...

Applies to most patients with one or two positive sentinel lymph nodes ...

Long-term follow-up consistent with earlier report, a hint of benefit in high-grade diseas ...

An investigator reported 10-year follow-up data from a phase 3 trial of extended vs limited pelvic lymph node dissection during radical prostatectomy.

Results from the PHENIX-I trial support skipping pelvic lymphadenectomy in women with early cervical cancer who have a negative sentinel lymph node biopsy. Omitting pelvic lymphadenectomy in these ...

Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in ...

Extended dissection did not improve recurrence-free or overall survival, but it may have a bladder cancer-specific survival benefit possibly because it removes micrometastases. Extended lymph node ...

In a trial, selected patients with early non-small cell lung cancer did not benefit from mediastinal lymph node dissection (LND). Mediastinal LND resulted in longer surgeries, increased bleeding, and ...